# Dexilant Solutab (dexlansoprazole) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dexlansoprazole

> The FDA approved Dexilant Solutab (dexlansoprazole), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on January 26, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Dexilant Solutab (dexlansoprazole) |
| Codes |  |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Erosive Esophagitis](https://sec-api.dev/indications/erosive-esophagitis), Gastroesophageal Reflux Disease (GERD) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 26, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208056 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160126, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product DEXILANT SOLUTAB (DEXLANSOPRAZOLE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208056%22

### April 13, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Erosive Esophagitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02615184 (A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT02615184

### July 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Gastroesophageal Reflux Disease (GERD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02616302 (A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT02616302

## Same indication

- [NEXIUM-20MG](https://sec-api.dev/pdufa/nexium-20mg) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dexlansoprazole.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dexilant Solutab (dexlansoprazole) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dexlansoprazole

```bibtex
@misc{secapidev_pdufa_dexlansoprazole_20261116,
  title        = {Dexilant Solutab (dexlansoprazole) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dexlansoprazole}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dexlansoprazole_20261116","title":"Dexilant Solutab (dexlansoprazole) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dexlansoprazole","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
